Could some breast cancer patients skip radiation entirely?
NCT ID NCT07762885
First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This trial is asking whether women with a very early, non-invasive breast condition called ductal carcinoma in situ (DCIS) can safely skip radiation therapy after having breast-conserving surgery. The study focuses on women aged 40 and older with low- or intermediate-risk DCIS that is estrogen receptor-positive, small (≤2.5 cm), and has clear margins. Participants are randomly assigned to either receive standard radiation or no radiation, with all taking tamoxifen. The main goal is to see if skipping radiation leads to a similar rate of the cancer returning in the same breast within five years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Adjuvant radiotherapy (partial or whole breast irradiation) versus observation alone, with tamoxifen as background endocrine therapy
- What this could lead to
- If skipping radiation proves safe, many women with low-risk DCIS could avoid weeks of daily treatment and its side effects, without raising their risk of the cancer coming back.
- What could go wrong
- This is a non-inferiority trial, so it can only show that omitting radiation is not much worse than having it—not that it's better. The results may not apply to women with higher-risk features, and there is still a small chance that skipping radiation increases recurrence risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCTAL CARCINOMA IN SITU, DCIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.